玻璃体腔注射阿柏西普单药治疗1型早产儿视网膜病变的解剖与功能结果:一年结局
这项前瞻性队列研究纳入9例1型早产儿视网膜病变患者(17眼),以玻璃体腔注射阿柏西普(IVA)作为一线治疗并随访至少1年。单次注射后15眼(88.2%)病变消退,2眼(11.8%)需再次治疗;1年平均Snellen视力6/13±0.34,等效球镜-1.94±2.97 D,未观察到重大眼部并发症或全身不良反应,仅1例(11%)因肺部感染死亡。
要点
- 单次IVA使88.2%的1型ROP眼病变消退,11.8%需再次治疗。
- 1年平均视力6/13±0.34,屈光误差-1.94±2.97 D。
- 随访期间无重大眼部并发症或全身不良反应。
核心结论
- 阿柏西普治疗1型早产儿视网膜病变有效且耐受性良好,可获得良好的解剖、视力和屈光结局,是潜在治疗选择。
研究设计与样本
- 前瞻性队列研究,纳入2015年7月1日至2017年6月30日以IVA作为一线治疗的1型早产儿视网膜病变患者,随访至少1年。
- 共纳入9例患者17眼。
主要发现
- 单次IVA注射后15眼(88.2%)病变消退,2眼(11.8%)需要再次治疗。
- 1年平均Snellen视力为6/13±0.34,平均屈光误差为-1.94±2.97 D。
- 随访期间未观察到重大眼部并发症或全身不良反应,但1例患者(11%)在14月龄时因肺部感染死亡。
临床怎么用
- 对于1型早产儿视网膜病变,可考虑将IVA作为一线治疗选项之一。
- 治疗后需随访至少1年,关注病变消退、复发及再次治疗需求。
局限性
- 样本量小(9例17眼),可能限制结果的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the anatomical and functional outcomes of Type 1 retinopathy of prematurity 1 year after the intravitreal injection of aflibercept (IVA). METHODS: This prospective cohort study enrolled Type 1 retinopathy of prematurity patients who had been treated with IVA as first-line therapy from July 1, 2015, to June 30, 2017. Patients were followed up for at least 1 year after injection. The primary outcomes were retinopathy of prematurity regression, progression, reactivation, and the occurrence of associated complications after the use of IVA. The secondary outcomes were visual acuity and refractive error at 1 year after IVA. RESULTS: Seventeen eyes of nine patients were enrolled in our study. A single IVA injection resulted in resolution in 15 eyes (88.2%), whereas 2 eyes (11.8%) needed retreatment. The mean Snellen visual acuity and refractive error were 6/13 ± 0.34 and -1.94 ± 2.97 D, respectively. No major ocular complications or systemic adverse effects were noted during the follow-up period, except one patient (11%) passed away at the age of 14 months due to a pulmonary infection. CONCLUSION: Aflibercept is effective and well tolerated for the treatment of Type 1 retinopathy of prematurity; it is a potential treatment option as it achieves good anatomical, visual, and refractive outcomes.
引用
- Chen YT, Liu L, Lai CC, et al. ANATOMICAL AND FUNCTIONAL RESULTS OF INTRAVITREAL AFLIBERCEPT MONOTHERAPY FOR TYPE 1 RETINOPATHY OF PREMATURITY: One-Year Outcomes. Retina. 2020. PMID: 31996587. doi:10.1097/IAE.0000000000002754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。